Global Targeted DNA RNA Sequencing Market size and share is currently valued at USD 12.02 billion in 2024 and is anticipated to generate an estimated revenue of USD 70.79 billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 19.4% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 - 2034
In contrast to whole-genome sequencing, targeted sequencing employs curated panels—such as NGS panels—that focus on clinically relevant genes or transcripts. These methods have become vital tools in molecular diagnostics, aiding in the detection of disease-causing mutations, monitoring therapeutic responses, and guiding precision treatments across a range of conditions, particularly in oncology and inherited disorders.
Key Applications and Benefits
- Amplicon sequencing enables deep sequencing of targeted regions with minimal sample input and fast turnaround times.
- Gene expression profiling allows researchers to monitor the activity of genes and understand the molecular mechanisms of diseases.
- NGS panels offer customizable solutions tailored to specific clinical or research needs.
- Molecular diagnostics powered by targeted sequencing are revolutionizing the way clinicians diagnose and treat diseases, including rare genetic conditions and complex cancers.
Country-wise Market Trends
United States
The U.S. remains the epicenter of global targeted DNA/RNA sequencing efforts, thanks to its advanced research infrastructure and strong federal support for precision medicine. The NIH’s All of Us Research Program continues to expand its genomic database, encouraging the integration of targeted sequencing into routine care.
In clinical practice, the U.S. has been a first-mover in adopting NGS panels for oncology, reproductive health, and pharmacogenomics. Hospitals and laboratories increasingly rely on targeted methods to inform therapeutic decisions, especially in cancer care. Moreover, the FDA’s progressive regulatory framework for NGS-based tests is fostering innovation and market penetration.
copyright
copyright has seen a surge in targeted sequencing utilization through national efforts like Genome copyright and provincial healthcare initiatives that focus on rare diseases and cancer genomics. Canadian researchers are using gene expression profiling in precision oncology trials, while hospitals deploy amplicon sequencing methods to diagnose hereditary syndromes with greater speed and precision.
Infectious disease monitoring, especially during the COVID-19 pandemic, has also accelerated the implementation of targeted sequencing techniques to identify and track viral variants.
United Kingdom
The UK stands out with its robust genomics initiatives, including the 100,000 Genomes Project, which has laid the foundation for integrating NGS into the National Health Service (NHS). Targeted sequencing has become a critical part of rare disease diagnosis and cancer treatment planning.
The NHS is adopting molecular diagnostics at scale, employing NGS panels to support personalized treatment regimens. Additionally, collaborations between universities and the NHS are driving innovation in gene expression profiling, aiding in biomarker discovery and clinical research.
Germany
Germany is one of Europe's leading hubs for genomics and biotechnology, with a strong focus on integrating NGS into diagnostic laboratories. Federal initiatives are promoting the adoption of targeted sequencing in oncology and neurology.
German academic institutions are also developing high-throughput amplicon sequencing workflows for research and translational medicine. Additionally, digital health integration and government incentives are facilitating wider clinical use of NGS panels across hospitals and research centers.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/targeted-dna-rna-sequencing-market
France
France’s national genomics strategy, France Médecine Génomique 2025, aims to mainstream genomic medicine, with targeted sequencing as a core component. The country is rapidly expanding its network of sequencing platforms to offer precise molecular diagnostics for both rare and common diseases.
French institutions are advancing the use of gene expression profiling for early cancer detection and immune response studies, reflecting a shift toward preventative medicine and personalized interventions.
China
China is experiencing exponential growth in the targeted DNA/RNA sequencing market, driven by large-scale genomic initiatives and government investment. National projects like China Precision Medicine Initiative are promoting genetic testing for disease prevention and individualized therapy.
Targeted sequencing is being widely applied in oncology, reproductive health, and infectious disease surveillance. Public health agencies are employing amplicon sequencing for pathogen detection and outbreak tracking. The country's push toward local innovation and biotech infrastructure is expected to sustain high growth in the coming years.
Japan
Japan has embraced targeted sequencing through national health programs and academic-industry collaborations. The country is using NGS panels in routine diagnostics for cancer and genetic disorders, supported by the Ministry of Health’s reimbursement policies for genomic testing.
Japan is also a leader in automation and miniaturization of molecular diagnostics, with efforts to develop compact systems that bring sequencing closer to point-of-care environments. Research in gene expression profiling is accelerating in neuroscience and metabolic disease sectors.
South Korea
South Korea's well-developed healthcare system and digital infrastructure are facilitating the rapid integration of NGS technologies. Government initiatives such as Genome Korea are focusing on collecting population-scale genomic data to support the development of targeted therapies.
Hospitals are deploying NGS panels to identify actionable mutations in oncology and rare diseases. Additionally, the adoption of amplicon sequencing for prenatal testing and infectious disease diagnostics is increasing in both public and private sectors.
India
India is emerging as a significant market for targeted sequencing, driven by a growing burden of genetic disorders and cancers. Cost-effective amplicon sequencing and gene expression profiling tools are being adopted by diagnostic labs and research institutes to address local healthcare challenges.
The Indian government is supporting genomics through programs like IndiGen, which aims to map genetic diversity across ethnic groups. Targeted sequencing is also gaining ground in pharmacogenomics and tuberculosis diagnostics.
Brazil
In Latin America, Brazil is leading the adoption of NGS technologies, especially in cancer genomics and infectious disease monitoring. Public health institutions are using molecular diagnostics to guide cancer treatment and track outbreaks of diseases like dengue and Zika.
Brazilian research centers are investing in NGS panels and targeted sequencing pipelines for population studies and personalized healthcare applications. However, broader adoption is challenged by budget constraints and the need for local infrastructure.
United Arab Emirates
The UAE is positioning itself as a genomic innovation hub in the Middle East. With projects like the Emirati Genome Program, the nation is implementing targeted DNA/RNA sequencing to develop population-specific reference genomes and tailor healthcare services.
Sequencing facilities in the UAE are using gene expression profiling and NGS panels to improve clinical diagnostics, particularly in oncology and metabolic disorders. The country's strategic vision to become a leader in precision medicine is driving substantial investment in genomics.
South Africa
In Africa, South Africa is at the forefront of applying targeted sequencing in both research and clinical settings. The South African Human Genome Programme and collaborations with global research networks are enhancing understanding of disease genetics in underrepresented populations.
Efforts are being made to implement amplicon sequencing for HIV and tuberculosis drug resistance profiling. Although infrastructure gaps remain, growing interest in genomics is paving the way for scalable molecular diagnostics solutions across the continent.
Conclusion
The global Targeted DNA/RNA Sequencing Market is accelerating as countries around the world integrate genomics into their healthcare systems. Driven by applications in oncology, rare diseases, infectious diseases, and preventative medicine, targeted sequencing offers a focused, cost-effective, and clinically relevant alternative to broader genomic approaches.
More Trending Latest Reports By Polaris Market Research:
Infectious Disease Diagnostics Market
Car Camera Cleaning Systems Market
Oyster and Clam Market
Recruitment Process Outsourcing Market
3D Printing Metals Market
Ultrasound Probe Cover Market: A Sanitized Approach to Staff Efficacy and Patient Safety
Rigid Plastic Packaging Market
Food Amino Acids Market
Cell Therapy Market